SLE (SYSTEMIC LUPUS)
Clinical trials for SLE (SYSTEMIC LUPUS) explained in plain language.
Never miss a new study
Get alerted when new SLE (SYSTEMIC LUPUS) trials appear
Sign up with your email to follow new studies for SLE (SYSTEMIC LUPUS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill VENT-03 aims to calm lupus skin flares
Disease control Recruiting nowThis study tests whether VENT-03, a tablet, can reduce skin inflammation in people with active cutaneous lupus (with or without systemic lupus). 24 adults will take VENT-03 or a placebo for 4 weeks, then everyone gets VENT-03 for 8 more weeks. Researchers will check skin severity…
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: PHASE2 • Sponsor: Ventus Therapeutics U.S., Inc. • Aim: Disease control
Last updated Jun 22, 2026 11:57 UTC
-
Gene-Edited cells take on lupus and scleroderma in first human test
Disease control Recruiting nowThis early-stage trial tests a single infusion of CRISPR-edited immune cells (CTX112) from a healthy donor in 80 adults with severe lupus, scleroderma, or myositis that hasn't responded to standard treatments. The goal is to see if the cells are safe and can reduce disease activi…
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: PHASE1 • Sponsor: CRISPR Therapeutics • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
Immune reset: CAR-T therapy targets lupus and other autoimmune conditions
Disease control Recruiting nowThis early-stage study is testing a new treatment using a patient's own immune cells, modified to target and attack faulty immune cells that cause autoimmune diseases like lupus, scleroderma, and Sjogren's syndrome. The goal is to see if this approach is safe and can control dise…
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 16, 2026 12:50 UTC
-
New lupus drug CLN-978 enters early human testing
Disease control Recruiting nowThis early-stage study tests a new drug called CLN-978 in 24 people with moderate to severe lupus. The main goal is to see if the drug is safe and tolerable. Researchers will also measure how the drug moves through the body and how it affects immune cells. This is a first step to…
Matched conditions: SLE (SYSTEMIC LUPUS)
Phase: PHASE1 • Sponsor: Cullinan Therapeutics Inc. • Aim: Disease control
Last updated Jun 15, 2026 18:54 UTC